Creation of a chemotherapy-induced nausea/vomiting dashboard to improve outcomes for pediatric cancer patients
- 1 March 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in Supportive Care in Cancer
- Vol. 29 (3), 1549-1555
- https://doi.org/10.1007/s00520-020-05652-1
Abstract
Purpose Two of the most common acute side effects of chemotherapy are nausea and vomiting. Nausea and vomiting impact quality of life, nutritional status, and ability to tolerate further chemotherapy. Parents of pediatric oncology patients rank nausea as one of the most bothersome treatment-related symptoms. Methods Utilizing Quality Improvement methodology, we developed a dashboard interface to facilitate extraction of data from the electronic medical record (EMR), which is presented via a visual display that summarizes the type of chemotherapy and antiemetic medications, use of as needed medications, and number of episodes of emesis. Results This dashboard interface allows for rapid and efficient identification of patients whose antiemetic regimen is mismatched for the emetogenicity of ordered chemotherapy, thus providing a timely opportunity to modify the antiemetic regimen based on published guidelines before administration of chemotherapy drugs. It also allows measurement of the effectiveness of the antiemetic regimen in terms of the number of break through emesis and the need for as needed medications. Conclusions A novel CINV dashboard was created, which visually conveys complex information about antiemetics, chemotherapy emetogenicity, as needed medications, and breakthrough vomiting for inpatient pediatric oncology patients.Keywords
This publication has 30 references indexed in Scilit:
- A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapyAnnals Of Oncology, 2014
- Adherence to antiemetic guidelines in patients with malignant glioma: a quality improvement project to translate evidence into practiceSupportive Care in Cancer, 2014
- International antiemetic guidelines on chemotherapy induced nausea and vomiting (CINV): Content and implementation in daily routine practiceEuropean Journal of Pharmacology, 2014
- Guideline for the prevention of acute nausea and vomiting due to antineoplastic medication in pediatric cancer patientsPediatric Blood & Cancer, 2013
- Aprepitant plus palonosetron and dexamethasone for prevention of chemotherapy‐induced nausea and vomiting in patients receiving multiple‐day cisplatin chemotherapyInternal Medicine Journal, 2013
- The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): the Pan European Emesis Registry (PEER)Annals Of Oncology, 2012
- Guideline for the classification of the acute emetogenic potential of antineoplastic medication in pediatric cancer patientsPediatric Blood & Cancer, 2011
- Symptom assessment in children receiving cancer therapy: the parents’ perspectiveSupportive Care in Cancer, 2009
- Diffusion Theory and Knowledge Dissemination, Utilization, and Integration in Public HealthAnnual Review of Public Health, 2009
- Development and Validation of the Pediatric Nausea Assessment Tool for Use in Children Receiving Antineoplastic AgentsPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2006